Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.


INTRODUCTION Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Despite the availability of several disease-modifying therapies for relapsing MS, there is a need for highly efficacious targeted therapy with a favorable benefit-risk profile and a high level of treatment adherence. Daclizumab is a humanized… (More)
DOI: 10.1080/17425255.2018.1432594


  • Presentations referencing similar topics